Results 121 to 130 of about 2,396,041 (352)
We quantified and cultured circulating tumor cells (CTCs) of 62 patients with various cancer types and generated CTC‐derived tumoroid models from two salivary gland cancer patients. Cellular liquid biopsy‐derived information enabled molecular genetic assessment of systemic disease heterogeneity and functional testing for therapy selection in both ...
Nataša Stojanović Gužvić+31 more
wiley +1 more source
This study simultaneously investigated circulating tumor cells (CTCs) and exosomes from small‐cell lung cancer (SCLC) patients. The elevated expression of JUNB and CXCR4 in CTCs was a poor prognostic factor for SCLC patients, whereas exosomal overexpression of these biomarkers revealed a high discrimination ability of patients from healthy individuals,
Dimitrios Papakonstantinou+13 more
wiley +1 more source
Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models. [PDF]
Conroy F+16 more
europepmc +1 more source
The Chemical Engineering of the Hardwood Distillation Industry [PDF]
James R. Withrow
openalex +1 more source
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou+11 more
wiley +1 more source
Electrochemical-induced phosphorylation of arenols and tyrosine containing oligopeptides
Summary: A disclosed technique employs electrochemical dehydrogenative cross-coupling to create organophosphates, utilizing phosphites compounds with arenols.
Rong Sun+9 more
doaj
Pre-lab video demonstrations to enhance students' laboratory experience in a first-year chemical engineering class. [PDF]
Onyeaka H+6 more
europepmc +1 more source
Approximate operational calculus in chemical engineering [PDF]
Stuart W. Churchill
openalex +1 more source
Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia+17 more
wiley +1 more source